287 related articles for article (PubMed ID: 24468315)
21. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
[TBL] [Abstract][Full Text] [Related]
22. Current treatment approaches for NK/T-cell lymphoma.
Yamaguchi M; Miyazaki K
J Clin Exp Hematop; 2017 Dec; 57(3):98-108. PubMed ID: 28679966
[TBL] [Abstract][Full Text] [Related]
23. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
Yamaguchi M; Suzuki R; Oguchi M; Asano N; Amaki J; Akiba T; Maeda T; Itasaka S; Kubota N; Saito Y; Kobayashi Y; Itami J; Ueda K; Miyazaki K; Ii N; Tomita N; Sekiguchi N; Takizawa J; Saito B; Murayama T; Ando T; Wada H; Hyo R; Ejima Y; Hasegawa M; Katayama N
J Clin Oncol; 2017 Jan; 35(1):32-39. PubMed ID: 28034070
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and management of natural killer-cell malignancies.
Ishida F; Kwong YL
Expert Rev Hematol; 2010 Oct; 3(5):593-602. PubMed ID: 21083476
[TBL] [Abstract][Full Text] [Related]
25. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia.
Suzuki R
Int J Hematol; 2010 Dec; 92(5):697-701. PubMed ID: 21116747
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type.
Ennishi D; Maeda Y; Fujii N; Kondo E; Shinagawa K; Ikeda K; Ichimura K; Yoshino T; Tanimoto M
Leuk Lymphoma; 2011 Jul; 52(7):1255-61. PubMed ID: 21599584
[TBL] [Abstract][Full Text] [Related]
27. [Advances of treatment for extranodal NK/T-cell lymphoma --- review].
Zhang SS; Wei M; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):1075-8. PubMed ID: 21867647
[TBL] [Abstract][Full Text] [Related]
28. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
[TBL] [Abstract][Full Text] [Related]
29. Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type.
Liang R
Br J Haematol; 2009 Oct; 147(1):13-21. PubMed ID: 19604234
[TBL] [Abstract][Full Text] [Related]
30. Risk stratification in extranodal natural killer/T-cell lymphoma.
Kohrt H; Lee M; Advani R
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1395-405. PubMed ID: 20836675
[TBL] [Abstract][Full Text] [Related]
31. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
[TBL] [Abstract][Full Text] [Related]
32. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues.
Suzuki R; Takeuchi K; Ohshima K; Nakamura S
Hematol Oncol; 2008 Jun; 26(2):66-72. PubMed ID: 18283711
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
Wen JY; Li M; Li X; Chen J; Lin Q; Ma XK; Dong M; Wei L; Chen ZH; Wu XY
Asian Pac J Cancer Prev; 2014; 15(15):6275-81. PubMed ID: 25124611
[TBL] [Abstract][Full Text] [Related]
34. Management of extranodal natural killer/t-cell lymphoma, nasal type.
Chaudhary RK; Bhatt VR; Vose JM
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):245-52. PubMed ID: 25659751
[TBL] [Abstract][Full Text] [Related]
35. NK/T-cell lymphomas: pathobiology, prognosis and treatment paradigm.
Suzuki R
Curr Oncol Rep; 2012 Oct; 14(5):395-402. PubMed ID: 22639106
[TBL] [Abstract][Full Text] [Related]
36. How we treat NK/T-cell lymphomas.
Tse E; Zhao WL; Xiong J; Kwong YL
J Hematol Oncol; 2022 Jun; 15(1):74. PubMed ID: 35659326
[TBL] [Abstract][Full Text] [Related]
37. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
[TBL] [Abstract][Full Text] [Related]
39. Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell Lymphoma, nasal type (ENKL): differences in biologic and clinical behaviors of LMP1-positive and -negative ENKL.
Kanemitsu N; Isobe Y; Masuda A; Momose S; Higashi M; Tamaru J; Sugimoto K; Komatsu N
Clin Cancer Res; 2012 Apr; 18(8):2164-72. PubMed ID: 22371452
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate-associated lymphoproliferative disorder presenting as extranodal NK/T-cell lymphoma arising in the lungs.
Tajima S; Takanashi Y; Koda K; Fukayama M
Pathol Int; 2015 Dec; 65(12):661-5. PubMed ID: 26459854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]